Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies

D. Rossini, A. Sbrana, F. Bergamo, C. Manai, D. Santini, M. Ghidini, C. Antoniotti, R. Moretto, F. Marmorino, F. Urbano, M. Ronzoni, S. Noventa, G. Randon, C. Carlomagno, T. Latiano, S. Cordio, C. Granetto, C. Cremolini, A. Falcone, A. Antonuzzo

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)iv114-iv115
JournalAnnals of oncology : official journal of the European Society for Medical Oncology
Volume30
DOIs
Publication statusPublished - Jul 1 2019

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Rossini, D., Sbrana, A., Bergamo, F., Manai, C., Santini, D., Ghidini, M., Antoniotti, C., Moretto, R., Marmorino, F., Urbano, F., Ronzoni, M., Noventa, S., Randon, G., Carlomagno, C., Latiano, T., Cordio, S., Granetto, C., Cremolini, C., Falcone, A., & Antonuzzo, A. (2019). Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies. Annals of oncology : official journal of the European Society for Medical Oncology, 30, iv114-iv115. https://doi.org/10.1093/annonc/mdz156.014